5AM Venture Management, LLC
SAN FRANCISCO, CA · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 16, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$297.0M2026 Q3
Positions16
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.91.2%
Top Holdings
LTGO
Latigo Biotherapeutics
41.2%
TRDA
Entrada Therapeutics
8.1%
TYRA
Tyra Biosciences
7.6%
CAMP
Camp4 Therapeutics
7.2%
ARTV
Artiva Biotherapeutics
5.6%
PHVS
Pharvaris N.V.
5.1%
TECX
Tectonic Therapeutic
4.8%
CLDX
Celldex Therapeutics
4.6%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.